BUSINESS● LOW2h ago · Oct 30, 2026, 1:16 PM
Agios falls on review extension for Pyrukynd label expansion
Seeking Alpha Tech · global
Agios stock fell due to an extended review period for its drug Pyrukynd's label expansion. This impacts the company's market performance.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS25m agoFederated Hermes expects $7B MDT equity additions as $6.5B pipeline is set to fund over next 2 quartersSeeking Alpha TechBUSINESS27m agoNew federal rule requires drug middlemen to disclose how they’re paidThe Hill